|
|
Volumn 15, Issue 3, 2001, Pages 227-229
|
|
Glyburide and fetal safety; transplacental pharmacokinetic considerations
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
GLIBENCLAMIDE;
ION;
ADULT;
BLOOD PLACENTA BARRIER;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG HALF LIFE;
DRUG MECHANISM;
FEMALE;
FETOMATERNAL TRANSFUSION;
FETUS;
FETUS DISEASE;
HUMAN;
HYPERINSULINEMIA;
HYPOGLYCEMIA;
LIPID SOLUBILITY;
MOLECULAR WEIGHT;
PLACENTA;
PLACENTAL TRANSFER;
PREGNANCY;
PREGNANCY COMPLICATION;
PREGNANCY DIABETES MELLITUS;
PROTEIN BINDING;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
|
|
EID: 0034968488
PISSN: 08906238
EISSN: None
Source Type: Journal
DOI: 10.1016/S0890-6238(01)00122-8 Document Type: Note |
|
Times cited : (66)
|
|
References (6)
|
